N-Cyclohexylcyclobutancarboxamid | 15911-05-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-Cyclohexylcyclobutancarboxamid
• 英文别名: N-cyclohexylcyclobutanecarboxamide
• CAS: 15911-05-4
• 化学式: C₁₁H₁₉NO
• mdl: MFCD03131542
• 分子量: 181.278
• InChiKey: AGKWHGDRIIUSEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.909
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• OXADIAZOLE DERIVATIVES USEFUL AS HDAC INHIBITORS
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP3325475A1

  公开（公告）日：2018-05-30
• Tyrosine Derivatives As Ppar-Gamma-Modulators
  申请人：Serra Comas Carmen

  公开号：US20070276043A1

  公开（公告）日：2007-11-29

  Compounds of general formula I, and the salts and solvates thereof, wherein R1 represents the radical 2-benzoylphenylamino; R2 represents —(CH 2 ) s —N(COR 3 )-A-J-T or —(CH 2 ) S —N(R 4 )—B-J-T; and s, R3, R4, A, B, J and T have the meanings disclosed in the description. These compounds are PPARγ modulators and, therefore, are useful for the treatment or prevention of a condition or a disease mediated by these receptors.
• NEW TYROSINE DERIVATIVES AS PPARy MODULATORS
  申请人：SERRA COMAS Carmen

  公开号：US20090088438A1

  公开（公告）日：2009-04-02

  Compounds of general formula I, and the salts and solvates thereof, wherein R1 represents the radical 2-benzoylphenylamino; R2 represents —(CH 2 ) s —N(COR3)-A-J-T or —(CH 2 ) s —N(R4)-B-J-T; and s, R3, R4, A, B, J and T have the meanings disclosed herein. These compounds are PPARγ modulators and, therefore, are useful for the treatment or prevention of a condition or a disease mediated by these receptors.
• US7423172B2
  申请人：——

  公开号：US7423172B2

  公开（公告）日：2008-09-09
• [EN] OXADIAZOLE DERIVATIVES USEFUL AS HDAC INHIBITORS<br/>[FR] DÉRIVÉS OXADIAZOLE UTILES EN TANT QU'INHIBITEURS DE HDAC
  申请人：TAKEDA PHARMACEUTICALS CO

  公开号：WO2017014321A1

  公开（公告）日：2017-01-26

  The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a pharmaceutical composition comprising the compound. The present invention relates to a compound represented by the formula (I) : wherein each symbol is as defined in the specification, or a salt thereof.